GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baxalta Inc (NYSE:BXLT) » Definitions » Cash Flow from Investing

Baxalta (Baxalta) Cash Flow from Investing : $-2,294 Mil (TTM As of Mar. 2016)


View and export this data going back to 2015. Start your Free Trial

What is Baxalta Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2016, Baxalta spent $235 Mil on purchasing property, plant, equipment. It gained $0 Mil from selling property, plant, and equipment. It spent $280 Mil on purchasing business. It gained $0 Mil from selling business. It spent $0 Mil on purchasing investments. It gained $0 Mil from selling investments. It paid $0Mil for net Intangibles purchase and sale. And it paid $33 Mil for other investing activities. In all, Baxalta spent $548 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2016.


Baxalta Cash Flow from Investing Historical Data

The historical data trend for Baxalta's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baxalta Cash Flow from Investing Chart

Baxalta Annual Data
Trend Dec12 Dec13 Dec14 Dec15
Cash Flow from Investing
-697.00 -977.00 -501.00 -2,293.00

Baxalta Quarterly Data
Dec12 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -547.00 -293.00 -1,123.00 -330.00 -548.00

Baxalta Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Baxalta's Cash Flow from Investing for the fiscal year that ended in Dec. 2015 is calculated as:

Baxalta's Cash Flow from Investing for the quarter that ended in Mar. 2016 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2,294 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Baxalta  (NYSE:BXLT) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Baxalta's purchase of property, plant, equipment for the three months ended in Mar. 2016 was $-235 Mil. It means Baxalta spent $235 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Baxalta's sale of property, plant, equipment for the three months ended in Mar. 2016 was $0 Mil. It means Baxalta gained $0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Baxalta's purchase of business for the three months ended in Mar. 2016 was $-280 Mil. It means Baxalta spent $280 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Baxalta's sale of business for the three months ended in Mar. 2016 was $0 Mil. It means Baxalta gained $0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Baxalta's purchase of investment for the three months ended in Mar. 2016 was $0 Mil. It means Baxalta spent {stock_data.stock.currency_symbol}}0 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Baxalta's sale of investment for the three months ended in Mar. 2016 was $0 Mil. It means Baxalta gained $0 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Baxalta's net Intangibles purchase and sale for the three months ended in Mar. 2016 was $0 Mil. It means Baxalta paid $0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Baxalta's cash from discontinued investing activities for the three months ended in Mar. 2016 was 0 Mil. It means Baxalta paid $0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Baxalta's cash from other investing activities for the three months ended in Mar. 2016 was $-33 Mil. It means Baxalta paid $33 Mil for other investing activities.


Baxalta Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Baxalta's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Baxalta (Baxalta) Business Description

Traded in Other Exchanges
N/A
Address
Baxalta Inc was incorporated on September 8, 2016. It is a biopharmaceutical company engaged in the field of unmet medical needs covering various diseases which includes haemophilia, immunology and oncology. The Company develops, manufactures and markets a diverse portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia. It also invests in emerging technology platforms, including gene therapy and biosimilars. Its competitors include Advate, Feiba, Gammagard. The Company is subject to rules and regulations put forth by the jurisdiction it operates in.
Executives
Gail D Fosler director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
John Glasspool officer: See Remarks C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Dagmar Rosa-bjorkeson officer: EVP and President, Biosimilars C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
David D. Meek officer: EVP and President, Oncology 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Karen Jean Ferrante director 150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Peter G Edwards officer: SVP and General Counsel C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Robert J. Hombach officer: EVP. CFO and COO C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Blake E Devitt director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Wayne T Hockmeyer director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anne-marie Law officer: EVP & Head of Human Resources C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Stroucken Albert P L director BAXTER INTERNATIONAL INC., ONE BAXTER PARKWAY, DEERFIELD IL 60015
Gavin James R Iii director BAXTER INTERNATIONAL INC, ONE BAXTER PARKWAY, DEERFIELD IL 60015
John D Forsyth director C/O BAXTER INTERNATIONAL, ONE BAXTER PARKWAY, DEERFIELD IL 60015
Ludwig Hantson director, officer: President and CEO C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Francois Nader director 550 HILLS DRIVE, BEDMINSTER NJ 07921

Baxalta (Baxalta) Headlines

From GuruFocus

Daniel Loeb Comments on Seven & i Holdings

By Holly LaFon 11-03-2015

Third Avenue Management Comments on Baxalta

By Holly LaFon Holly LaFon 03-29-2016

Third Avenue Management Comments on Baxalta

By Holly LaFon Holly LaFon 12-10-2015

Tweedy Browne Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon 01-27-2016

Is Baxalta a Good Spin-Off Opportunity?

By Raman Minhas Raman Minhas 10-15-2015

Keeley Funds Comments on Baxalta Inc.

By Holly LaFon Holly LaFon 02-03-2016

Undervalued Baxalta Shares Target of Acquisition by Shire Plc

By Ben Reynolds Ben Reynolds 08-05-2015

Baxalta Vs. AbbVie: Biopharma Spin-Off Battle

By Ben Reynolds Ben Reynolds 08-20-2015

Jeff Auxier Sells Precision Castparts, AT&T, Microsoft

By Tiziano Frateschi Tiziano Frateschi 06-23-2016